Viking Therapeutics, Inc. Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss
Viking Therapeutics, Inc. (VKTX) had Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss of $101.00 thousand as of 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss · last filed 2018-08-09
- 2018-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $101.00K.
- 2017-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $19.00K; Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss as first filed $19.00K.
- 2017-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $3.32K.
- 2017-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $6.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss | Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss as first filed |
|---|---|---|
| 2018-03-31 | $101.00K 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $19.00K 10-Q · filed 2018-08-09 | $19.00K 10-K · filed 2018-03-07 |
| 2017-09-30 | $3.32K 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $6.00K 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $7.54K 10-Q · filed 2017-05-10 | |
| 2016-09-30 | $7.14K 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $6.85K 10-Q · filed 2016-08-11 | |
| 2015-12-31 | $7.37K 10-K · filed 2017-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |